Strong interim safety and efficacy data from Hoth Therapeutics Inc.’s phase IIa study of HT-001 helped boost the company’s stock (NASDAQ:HOTH) on Jan. 7 as shares rose 178% to close at $2.28 each.
Kaken Pharmaceutical Co. Ltd. and Johnson & Johnson (J&J) have entered into a license agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), developed by Kaken.
A new method to diagnose skin cancer was validated for the first time in clinical trials that show Dermr Health Solutions Pty Ltd.’s non-invasive microneedle patch collects near-equivalent genetic information compared to a skin biopsy without pain or cutting.
Deepcure Inc. has discovered potent, selective oral small-molecule inhibitors of STAT6. These next-generation STAT6 inhibitors have demonstrated promising oral bioavailability, cell permeability and metabolic stability, and do not target STAT6 for degradation.
Sunshine Lake Pharma Co Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of multiple sclerosis, psoriasis, rheumatoid arthritis, atopic dermatitis, scleroderma, lupus nephritis, systemic lupus erythematosus and ulcerative colitis, among others.
Onquality Pharmaceuticals China Ltd. has synthesized prodrugs of tofacitinib acting as JAK inhibitors reported to be useful for the treatment of atopic dermatitis, psoriasis and alopecia areata.
Disappointing readouts from separate phase II studies in atopic dermatitis sank shares of Q32 Bio Inc. and Anaptysbio Inc., as their respective antibody candidates failed to impress in a highly competitive space.
Astria Therapeutics Inc. has gained IND clearance from the FDA for STAR-0310, a monoclonal antibody OX40 antagonist being developed for atopic dermatitis.
RSS
